These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prolyl 4-hydroxylase, a target enzyme for drug development. Design of suppressive agents and the in vitro effects of inhibitors and proinhibitors.
    Author: Hanauske-Abel HM.
    Journal: J Hepatol; 1991; 13 Suppl 3():S8-15; discussion S16. PubMed ID: 1667671.
    Abstract:
    The hydrophilic compound pyridine 2,4-dicarboxylate (2,4-PDCA), designed as a mechanism-based competitive inhibitor of prolyl 4-hydroxylase, is efficiently excluded by the cytoplasmic membrane, but permeates the endoplasmic membrane via a 2,4-PDCA-selective translocator to reach its target enzyme in the intracisternal space. A lipophilic 2,4-PDCA-based proinhibitor, inactive with purified prolyl 4-hydroxylase, shows a cell system-dependent suppression of hydroxyprolyl formation, displaying a half-maximally inhibitory concentration very similar to the Ki of the parent compound. Apparently, cell-specific intracellular metabolic processing of the proinhibitor regenerates the active agent, 2,4-PDCA. The in vitro findings summarized here suggest that the 2,4-PDCA-mediated inhibition of prolyl 4-hydroxylase has a marked disruptive effect on the biosynthesis and deposition of collagen. This effect qualifies 2,4-PDCA and its derivatives as experimental fibrosuppressive compounds. However, to avoid catastrophic consequences in vivo, it is desirable to target the active agent to only the tissue that is compromised by excessive matrix formation. This requirement can be realized by the deliberate selection of an appropriate, 2,4-PDCA-based proinhibitor and by the deliberate selection of the route of proinhibitor administration.
    [Abstract] [Full Text] [Related] [New Search]